At the time of diagnosis, only about 20% of patients with pancreatic ductal adenocarcinoma
(PDAC) have resectable disease. PDAC treatment necessitates a multidisciplinary …

Background Neoadjuvant therapy is increasingly being used before surgery for localized
pancreatic cancer. Given the importance of completing multimodal therapy, the aim of this …

The NCCN Guidelines for Pancreatic Adenocarcinoma discuss the diagnosis and
management of adenocarcinomas of the exocrine pancreas and are intended to assist with …

Objectives: To establish an evidence-based cut-off to differentiate between early and late
recurrence and to compare clinicopathologic risk factors between the two groups. Summary …

Purpose To provide evidence-based recommendations to oncologists and others on
potentially curative therapy for patients with localized pancreatic cancer. Methods ASCO …

Objectives: To assess pancreatic fistula rate and secondary endpoints after
pancreatogastrostomy (PG) versus pancreatojejunostomy (PJ) for reconstruction in …

Background Pancreatic ductal adenocarcinoma are known to metastasise early and a
rationale exists for the investigation of preoperative chemotherapy in patients with …

Background Multiple trials have demonstrated a survival benefit for adjuvant chemotherapy
after resection of pancreatic adenocarcinoma. This study aimed to identify the rate for …

Background The relation between type of postoperative complication and not receiving
chemotherapy after resection of pancreatic ductal adenocarcinoma (PDAC) is unclear. The …

Background Composite outcomes may more accurately reflect patient and provider
expectations around optimal care. We sought to determine the impact of achieving a so …